THE FAUCI FILES: Toni The Confessor's Vaccine Patent Hypocrisy 
Author Message
 THE FAUCI FILES: Toni The Confessor's Vaccine Patent Hypocrisy

THE FAUCI FILES: Toni The Confessor's Vaccine Patent Hypocrisy
November 12, 1999

While Dr. Anthony Fauci has been one of the most avid readers
of The Fauci Files, it appears that the man is finally getting
the general idea about real science:

   "... They found that just three days after infection, the
    virus was in both activated and resting T-cells. In the
    following days, it spread faster and faster into the
    resting T-cells."

Let's go through some of the key scientific realities that
Fauci learned from THE FAUCI FILES -- in the words of
Fauci himself:

  THE FAUCI FILES: {*filter*} CAN NEVER ELIMINATE HIV.

    Toni: Virus in resting T-cells is a much more difficult target
          for both the immune system and for anti-viral {*filter*}

  THE FAUCI FILES: HIV VACCINES ARE LUDICROUS.

    Toni: (This is) "bad news for vaccines" because it makes it
           more difficult to inoculate the body against HIV infection.

Oddly enough, Fauci has a patent application pending for some "special"
HIV vaccine peptides (see the patent details following the AP article
below). Obviously, Direktor Fauci's IL-2 patent didn't pan out as
expected, despite Toni's desperate misrepresentations and misdirected
steering of research directions, screwed priorities and theft
of tax dollars funneled into fraudulent IL-2 "clinical studies".

So on the one hand, Toni "The Rat" Fauci admits that the vaccine
approach against HIV cannot possibly WORK, yet on the other hand
the little crook is busy claiming to be an inventor of some
"novel peptides" to use in HIV vaccine human experiments.

Even the subliminally impaired are beginning to figure out what's
going on with these...

Crooked {*filter*}ing Bastards!

fred

[NOTE: While Toni Fauci has been publicly mentioned as a leading
candidate for the job of NIH Director, there appear to be a few
"problems" that are have delayed Clinton's choice of Fauci.

While I've heard that THE FAUCI FILES are part of Toni's "problem"
(reported here with unbridled glee) -- it also is being reported
that George Bush offered the NIH Directorship to Fauci prior to
the selection of Harold Varmus -- and Fauci turned Bush down --
apparently Clinton's political instincts are serving him well in
not rushing to appoint a Republican choice for the job.

Naturally, as sole editor of THE FAUCI FILES, I must DEMAND that
Fauci be given the Director's job, so he can turn the rest
of the NIH institutes into Pharmaceutical {*filter*}s that will
require a version of THE FAUCI FILES to cover each institute
and perhaps every disease category!               fs. ]

======================================
Study: HIV Hides in Inactive WBC

By PAUL RECER
.c The Associated Press

WASHINGTON (AP) - A short time after it invades the body, the virus that

causes AIDS creates a reservoir of silent infection that cannot be
stamped out by current anti-viral {*filter*} and may resist vaccines, a study

shows.

The study, to be published Friday in the journal Science, sheds new
light on how quickly HIV, the virus that causes AIDS, is able to
establish a chronic, drug-resistant infection.

Earlier studies have shown that HIV establishes a reservoir of silent
infection. The new research shows that this disease pool is created
almost immediately after the virus is transmitted.

"These chronically infected cells are important because they allow the
virus to persist below the radar screen of the immune system,
particularly at the time of the transmission," said Dr. Ashley T.
Haase, an HIV researcher at the University of Minnesota and the senior
author of the study.

Haase said the study shows that a short time after the {*filter*}
transmission of the AIDS virus, there is an infection established in
what are known as resting T-cells. These are white {*filter*} cells that are
not actively participating in the body's immune response to the virus
and are resistant to anti-viral {*filter*}.

The finding is contrary to the belief that HIV first infects two other
targets, macrophages and dendritic cells, and then spreads to active T-
cells.

Instead, said Haase, the virus quickly moves in about equal proportions
into both the resting and the active T-cells.

Dr. Tony Fauci, director of the National Institute of Allergy and
Infectious Diseases at the National Institutes of Health, said the Haase

study "was a nice piece of work" that gives important new insight into
the early stages of HIV infection.

By quickly infecting the resting T-cells, said Fauci, the virus "gives
itself some insurance of survival." Virus in resting T-cells is a much
more difficult target for both the immune system and for anti-viral
{*filter*}, he said.

Fauci said the finding also is "bad news for vaccines" because it
makes it more difficult to inoculate the body against HIV infection.

In the study, Haase and his colleagues first studied the step-by-step
progress of AIDS virus infection in monkeys. The animals were {*filter*}lly
infected with SIV, the simian form of HIV. Researchers then took
specimens to trace the disease progress.

They found that just three days after infection, the virus was in both
activated and resting T-cells. In the following days, it spread faster
and faster into the resting T-cells.

Haase said his group then looked at specimens from patients recently
infected with HIV and found a similar pattern. The virus was present
about equally in both resting and activated T-cells, he said.

Virus in the resting T-cells is reproducing at a very, very low level,
said Haase. This makes the cells less obvious to the immune system. It
also creates a powerful defense against anti-virals because these {*filter*}
attack HIV only when the virus is actively reproducing.

The finding suggests that the current {*filter*} never will completely
eradicate the virus, he said.

Haase said it is believed that the resting T-cells can persist in the
body for years, perhaps decades. This means that the HIV in these cells
would remain a threat even though the {*filter*} reduce virus in the {*filter*}
stream to an undetectable level.

AP-NY-11-11-99 1707EST

[Federal Register: September 16, 1999 (Volume 64, Number 179)]
[Notices]              
[Page 50290]

Quote:
>From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr16se99-50]                        

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.

Novel HIV Related Peptides

Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci (NIAID)
Serial No. 60/132,760 filed 6 May 1999 (with priority to 11 Jan. 1999)
Licensing Contact: Robert Benson; 301/496-7056 ext. 267; e-mail:
rb20manih.gov

    This invention concerns novel peptides that selectively react with
sera from people who are HIV infected. The peptides were selected by
screening random peptide libraries displayed phages with sera from
long-term non-progressor (LTNP) subjects followed by counterscreening
with non-infected sera. The peptides are potentially useful as vaccines
against HIV, and to raise antisera for passive immunization against
HIV. In fact, the peptides behaved as antigenic mimics of linear or
conformational HIV-1 epitopes generated in vivo in subjects infected
with different HIV-1 strains and quasispecies. Moreover, the selected
epitopes fulfilled the requirements for an effective immunogen; in
fact, the inventors have shown that antisera from immunized mice
decrease HIV replication in an in vitro assay. Claimed are the
methodology, which allows the identification of pools of HIV-specific
peptides by taking advantage of the HIV-specific antibody repertoire
induced by the natural infection; peptides, alone or as part of larger
vaccine constructs; and antibodies raised against the peptides.



Tue, 30 Apr 2002 03:00:00 GMT
 
 [ 1 post ] 

 Relevant Pages 

1. The Fauci Files: Double-Dipping Toni?

2. THE FAUCI FILES: Team Reagan's Vaccine Epidemic (excerpt 10/29/99)

3. THE FAUCI FILES: Team Reagan's Vaccine Epidemic

4. THE FAUCI FILES, 3( 66): Dead Babies: Fauci's AZT African Legacy

5. THE FAUCI FILES, 3( 54): Exposing Fauci's CD4 Surrogate Marker Hoax

6. THE FAUCI FILES, 3( 66): Dead Babies: Fauci's AZT African Legacy

7. THE FAUCI FILES: The IL-2 Antiviral Hoax, U.S. Patent # US1995000452440

8. THE FAUCI FILES: Patent Fraud Trailblazing

9. THE FAUCI FILES: The IL-2 Antiviral Hoax, U.S. Patent # US1995000452440

10. ETHICS: TONI FAUCI'S FEMME DOMME PEAK EXPERIENCE

11. THE FAUCI FILES, Vol 2(32): Incompetent Contaminated Vaccine Human Experiments


 
Powered by phpBB® Forum Software